Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia
-
Stein, Eytan M. (Memorial Sloan Kettering Cancer Center (New York))
;
DeAngelo, Daniel J. (Dana-Farber Cancer Institute (Boston, Massachusetts)) ;
Chromik, Jörg (Goethe University Frankfurt) ;
Chatterjee, Manik (University Hospital of Würzburg) ;
Bauer, Sebastian (German Consortium of Translational Cancer Research (DKTK)) ;
Lin, Chia-Chi (National Taiwan University Hospital (Taipei, Taiwan)) ;
Suárez, Cristina (Vall d'Hebron Institut d'Oncologia) ;
de Vos, Filip (University Medical Center Utrecht) ;
Steeghs, Neeltje (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Cassier, Philippe A. (Léon Bérard Center) ;
Tai, David (National Cancer Center Singapore) ;
Kiladjian, Jean-Jacques (Université de Paris) ;
Yamamoto, Noboru (National Cancer Center Hospital (Tokyo, Japó)) ;
Mous, Rogier (University Medical Center Utrecht) ;
Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Minami, Hironobu (Kobe University Graduate School of Medicine and Hospital (Japó)) ;
Ferretti, Stephane (Novartis Institutes for Biomedical Research) ;
Guerreiro, Nelson (Novartis Institutes for Biomedical Research) ;
Meille, Christophe (Novartis Institutes for Biomedical Research) ;
Radhakrishnan, Rajkumar (Novartis Healthcare Private Limited (Hyderabad, India)) ;
Pereira, Bernard (Novartis Institutes for BioMedical Research (Cambridge, Massachusetts)) ;
Mariconti, Luisa (Novartis Institutes for Biomedical Research) ;
Halilovic, Ensar (Novartis Institutes for BioMedical Research (Cambridge, Massachusetts)) ;
Fabre, Claire (Novartis Institutes for Biomedical Research) ;
Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona